Literature DB >> 16280178

Cyclic nucleotide specific phosphodiesterases of the kinetoplastida: a unified nomenclature.

Stefan Kunz1, Joseph A Beavo, Maximiliano A D'Angelo, Mirtha M Flawia, Sharron H Francis, Andrea Johner, Sunil Laxman, Michael Oberholzer, Ana Rascon, Yasmin Shakur, Laurent Wentzinger, Roya Zoraghi, Thomas Seebeck.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16280178     DOI： 10.1016/j.molbiopara.2005.09.018

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN： 0166-6851            Impact factor:   1.759


× No keyword cloud information.
  12 in total

1.  Characterization of a novel cAMP-binding, cAMP-specific cyclic nucleotide phosphodiesterase (TcrPDEB1) from Trypanosoma cruzi.

Authors:  Rocío Díaz-Benjumea; Sunil Laxman; Thomas R Hinds; Joseph A Beavo; Ana Rascón
Journal:  Biochem J       Date:  2006-10-15       Impact factor: 3.857

2.  Phosphodiesterase inhibitors as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that are highly conserved between host and parasite.

Authors:  Thomas Seebeck; Geert Jan Sterk; Hengming Ke
Journal:  Future Med Chem       Date:  2011-08       Impact factor: 3.808

3.  The N terminus of phosphodiesterase TbrPDEB1 of Trypanosoma brucei contains the signal for integration into the flagellar skeleton.

Authors:  Edith Luginbuehl; Damaris Ryter; Judith Schranz-Zumkehr; Michael Oberholzer; Stefan Kunz; Thomas Seebeck
Journal:  Eukaryot Cell       Date:  2010-08-06

4.  Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.

Authors:  Huanchen Wang; Stefan Kunz; Gong Chen; Thomas Seebeck; Yiqian Wan; Howard Robinson; Sibylla Martinelli; Hengming Ke
Journal:  J Biol Chem       Date:  2012-02-21       Impact factor: 5.157

5.  Pharmacological validation of Trypanosoma brucei phosphodiesterases as novel drug targets.

Authors:  Harry P de Koning; Matthew K Gould; Geert Jan Sterk; Hermann Tenor; Stefan Kunz; Edith Luginbuehl; Thomas Seebeck
Journal:  J Infect Dis       Date:  2012-01-30       Impact factor: 5.226

6.  Crystal structure of the Leishmania major phosphodiesterase LmjPDEB1 and insight into the design of the parasite-selective inhibitors.

Authors:  Huanchen Wang; Zier Yan; Jie Geng; Stefan Kunz; Thomas Seebeck; Hengming Ke
Journal:  Mol Microbiol       Date:  2007-10-17       Impact factor: 3.501

7.  Gene conversion transfers the GAF-A domain of phosphodiesterase TbrPDEB1 to one allele of TbrPDEB2 of Trypanosoma brucei.

Authors:  Stefan Kunz; Edith Luginbuehl; Thomas Seebeck
Journal:  PLoS Negl Trop Dis       Date:  2009-06-09

8.  Cyclic nucleotide specific phosphodiesterases of Leishmania major.

Authors:  Andrea Johner; Stefan Kunz; Markus Linder; Yasmin Shakur; Thomas Seebeck
Journal:  BMC Microbiol       Date:  2006-03-08       Impact factor: 3.605

Review 9.  The ever unfolding story of cAMP signaling in trypanosomatids: vive la difference!

Authors:  Daniel N A Tagoe; Titilola D Kalejaiye; Harry P de Koning
Journal:  Front Pharmacol       Date:  2015-09-07       Impact factor: 5.810

10.  Cyclic AMP effectors in African trypanosomes revealed by genome-scale RNA interference library screening for resistance to the phosphodiesterase inhibitor CpdA.

Authors:  Matthew K Gould; Sabine Bachmaier; Juma A M Ali; Sam Alsford; Daniel N A Tagoe; Jane C Munday; Achim C Schnaufer; David Horn; Michael Boshart; Harry P de Koning
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.